The paradox of dysfunctional high-density lipoprotein
暂无分享,去创建一个
[1] D. Sviridov,et al. Genetic factors affecting HDL levels, structure, metabolism and function , 2007, Current opinion in lipidology.
[2] C. Jordan,et al. Group V Secretory Phospholipase A2 Promotes Atherosclerosis: Evidence From Genetically Altered Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[3] A. Tall,et al. The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[4] G. Kaysen. Disorders in high-density metabolism with insulin resistance and chronic kidney disease. , 2007, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[5] H. Pearson. When good cholesterol turns bad , 2006, Nature.
[6] Dan S. Tawfik,et al. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux Published, JLR Papers in Press, August 16, 2006.s⃞ , 2006, Journal of Lipid Research.
[7] A. Nègre-Salvayre,et al. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. , 2006, Free radical biology & medicine.
[8] G. Fonarow,et al. High-density lipoprotein: Is it always atheroprotective? , 2006, Current atherosclerosis reports.
[9] P. Barter,et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. , 2006, Journal of the American College of Cardiology.
[10] K. Kalunian,et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[11] G. Norata,et al. Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. , 2006, International journal of molecular medicine.
[12] M. Kamboh,et al. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. , 2006, Arthritis and rheumatism.
[13] Paul T. Tarr,et al. ATP-binding cassette transporter G1 and lipid homeostasis , 2006, Current opinion in lipidology.
[14] K. Wong,et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. , 2006, Clinical biochemistry.
[15] D. Sviridov,et al. Elevated HDL Cholesterol is Functionally Ineffective in Cardiac Transplant Recipients: Evidence for Impaired Reverse Cholesterol Transport , 2006, Transplantation.
[16] B. Lam,et al. HDL dysfunction in obstructive sleep apnea. , 2006, Atherosclerosis.
[17] C. Roberts,et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. , 2004, Journal of applied physiology.
[18] A. Nègre-Salvayre,et al. Structural modifications of HDL and functional consequences. , 2006, Atherosclerosis.
[19] T. Delmonte,et al. Evaluation of the Paraoxonases as Candidate Genes for Stroke: Gln192Arg Polymorphism in the Paraoxonase 1 Gene Is Associated With Increased Risk of Stroke , 2005, Stroke.
[20] J. Shepherd. Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes? , 2005, Atherosclerosis. Supplements.
[21] S. Reddy,et al. An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein E–Null Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[22] S. Hazen,et al. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. , 2005, Trends in cardiovascular medicine.
[23] A. Fogelman. When pouring water on the fire makes it burn brighter. , 2005, Cell metabolism.
[24] S. Reddy,et al. The double jeopardy of HDL , 2005, Annals of medicine.
[25] P. Barter. The inflammation: lipoprotein cycle. , 2005, Atherosclerosis. Supplements.
[26] S. Gabriel,et al. Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.
[27] P. Barter,et al. Antiinflammatory Properties of HDL , 2004 .
[28] Philippe Giral,et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. , 2004, The Journal of clinical endocrinology and metabolism.
[29] A. Hamsten,et al. Oxidised‐HDL3 induces the expression of PAI‐1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization , 2004, British journal of haematology.
[30] S. Reddy,et al. Oral D-4F Causes Formation of Pre-βHigh-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice , 2004, Circulation.
[31] M. Hersberger,et al. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease , 2004, Current opinion in lipidology.
[32] Aldons J Lusis,et al. Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.
[33] H. Brewer,et al. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[34] E. D. de Faria,et al. Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[35] Shirin Rahmani,et al. Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.
[36] Katsutoshi Yamada,et al. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. , 2003, Biochimica et biophysica acta.
[37] M. Hayden,et al. Efflux and Atherosclerosis: The Clinical and Biochemical Impact of Variations in the ABCA1 Gene , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[38] A. Hamsten,et al. Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. , 2003, International journal of molecular medicine.
[39] C. Marchionni,et al. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity , 2001, Acta Diabetologica.
[40] S. Reddy,et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.
[41] D. Nayak,et al. High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection , 2001, Circulation.
[42] G. Franceschini,et al. Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant: The Limone sul Garda Study , 2001, Circulation.
[43] S. Yamashita,et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. , 2000, Atherosclerosis.
[44] Hans Lee,et al. Determinants of Bioactivity of Oxidized Phospholipids: Specific Oxidized Fatty Acyl Groups at the sn-2 Position , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[45] S. Reddy,et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.
[46] J. Gamble,et al. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. , 2000, Journal of lipid research.
[47] S.-M. Kim,et al. Glycation impairs high-density lipoprotein function , 2000, Diabetologia.
[48] G. Fonarow,et al. formation of , 2022 .
[49] James W. Anderson,et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[50] J. Mehta,et al. Inhibition of arterial thrombus formation by ApoA1 Milano. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[51] M. Jensen-Urstad,et al. Vascular function correlates with risk factors for cardiovascular disease in a healthy population of 35‐year‐old subjects , 1997, Journal of internal medicine.
[52] J. Lidfeldt,et al. Blood pressure in relation to medical, psychological and social variables in a population of 80‐year‐olds. Survival during 6 years , 1997, Journal of internal medicine.
[53] R. D'Agostino,et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.
[54] D. Stafforini,et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.
[55] R. Stocker,et al. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[56] Y. Morino,et al. High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells. , 1992, Biochimica et biophysica acta.
[57] A. J. Valente,et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.
[58] J L Witztum,et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.
[59] C. Nathan,et al. Secretory products of macrophages. , 1987, The Journal of clinical investigation.
[60] G. Norata,et al. Oxidized-HDL 3 modulates the expression of Cox-2 in human endothelial cells , 2022 .